Riverwater Partners LLC Has $1 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Riverwater Partners LLC boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 102.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,182 shares of the medical equipment provider's stock after buying an additional 5,671 shares during the period. Riverwater Partners LLC's holdings in Lantheus were worth $1,000,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in Lantheus during the fourth quarter worth $36,183,000. Groupama Asset Managment acquired a new stake in shares of Lantheus during the 3rd quarter valued at about $439,000. Swedbank AB increased its stake in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after acquiring an additional 385,000 shares during the period. Keybank National Association OH acquired a new position in Lantheus in the fourth quarter worth about $27,526,000. Finally, Norges Bank bought a new position in Lantheus during the fourth quarter worth about $26,189,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

LNTH has been the subject of a number of recent research reports. JMP Securities reissued a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. B. Riley dropped their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price on the stock. Finally, Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Stock Performance

NASDAQ:LNTH traded down $4.09 during mid-day trading on Thursday, hitting $96.07. The company had a trading volume of 258,956 shares, compared to its average volume of 949,591. Lantheus Holdings, Inc. has a fifty-two week low of $58.46 and a fifty-two week high of $126.89. The firm has a market cap of $6.58 billion, a P/E ratio of 15.93 and a beta of 0.20. The business's fifty day moving average is $93.62 and its two-hundred day moving average is $95.76.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.